Circulating monocytes of FH patients not on statins showed a pro-inflammatory phenotype and intracellular lipid accumulation, which was reversed upon treatment with PCSK9 antibodies.
In T2DM patients with albuminuria, liraglutide treatment associates with reductions in circulating levels of CV risk biomarkers.
First study in humans to show a link between activity in the amygdala to subsequent CV events, likely via upregulation of haemopoietic tissue activity and increased atherosclerotic inflammation.
AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong.
Smoking heaviness independently related to urinary F2:Cr ratio, myeloperoxidase and WBC counts. F2:Cr ratio and WBC were also reduced after cessation.
The combination of the extent of carotid atherosclerosis and inflammatory status provided additional prognostic information for patients with asymptomatic carotid atherosclerosis.
CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.
Although the IL-1β inhibitor canakinumab reduced inflammation markers, there was no effect on measures of vascular structure or function in patients with T2DM and established CV disease.
The predictive ability of the Framingham Stroke Risk Profile score for incident ischaemic stroke was significantly improved with addition of 4 inflammatory biomarkers: CRP, tHcy, TNFR2, and VEGF.
After treatment with high-intensity statins, patients can still have residual cholesterol risk or residual inflammatory risk. This means that patients still have either high levels of LDL-c, but normal high sensitivity C-reactive protein (hsCRP) or normal LDL-c but high hsCRP
At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Kausik Ray spoke about therapeutic targets to further lower CV risk.
At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Jorge Plutzky spoke about BET inhibition as a nover pathway for CV risk reduction.